Prime Medicine Q3 Results: EPS beats estimate, sales up 244% YoY
Prime Medicine (PRME) reported Q3 EPS of $(0.22), beating estimates by 12%, and sales of $4.213M, up 244% YoY. The FDA cleared its PM647 drug for clinical trials, but shares fell 6.19%. The company aims to treat Alpha-1 Antitrypsin Deficiency with PM647, expecting initial trial data in 2027.
How this was made

The 30-second read
Why it matters
The combination of earnings beat and IND clearance generated a mixed market reaction, with the stock sliding as investors remain cautious about cash burn and future trial outcomes.
Market read
Primary biotech news with direct impact on PRME; limited spillover to broader market.
What to watch
Cash runway and upcoming trial costs may constrain near‑term upside despite the regulatory win.
Background
Prime Medicine is a biotech focused on prime editing therapies for liver diseases. The Q3 report showed a sharp revenue rise but still a loss per share.
Ticker impact
Prime Medicine reported Q3 earnings beat and FDA IND clearance for PM647, but shares fell 6.2% on the news.
likely continued modest downside as investors weigh the limited revenue against high cash burn
The earnings beat was modest and the IND clearance does not immediately translate to revenue; the stock already slipped, suggesting short‑term pressure.
Market effects
Highlights ongoing interest in liver‑directed gene editing, may boost sentiment for similar biotech peers.
Limited to US biotech sector; no broader regional effect.
Modest; FDA clearance is US‑specific and does not immediately affect global markets.
Counterpoint
The clearance could be a catalyst for a longer‑term rally if Phase 1/2 data prove compelling.
Key entities
- companyPrime Medicine Inc
NASDAQ‑listed biotech developing prime editing therapies.
- regulatorFDA
U.S. Food and Drug Administration, granted IND clearance for PM647.


